SCOTTSDALE, Ariz., April 3, 2009 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Medicis' United States patent application directed to the use of SOLODYN(R) in 90mg tablet form. For the week ending March 20, 2009, the 90mg strength represented over 60% of total SOLODYN(R) prescriptions.(1)
